Achieving Sustained Virological Response in Liver Transplant Recipients With Hepatitis C Decreases Risk of Decline in Renal Function

Sanjaya K. Satapathy, Kiran Joglekar, Miklos Z. Molnar, Bilal Ali, Humberto C. Gonzalez, Jason M. Vanatta, James D. Eason, Satheesh P. Nair – 23 March 2018 – The effect of antiviral therapy (AVT) on kidney function in liver transplantation (LT) recipients has not been well described despite known association of hepatitis C virus (HCV) infection with chronic kidney disease (CKD). We compared the incidence of CKD and end‐stage renal disease (ESRD) in 204 LT recipients with HCV based on treatment response to AVT.

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

Cristina B. Guzman, Suman Duvvuru, Anthony Akkari, Pallav Bhatnagar, Chakib Battioui, Wendra Foster, Xiaotian Michelle Zhang, Sudha S. Shankar, Mark A. Deeg, Naga Chalasani, Thomas A. Hardy, Christof M. Kazda, Sreekumar G. Pillai – 23 March 2018 – LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated alanine aminotransferases (ALTs) associated with LY2409021.

NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid

Kathy L. de Graaf, Geneviève Lapeyre, Florence Guilhot, Walter Ferlin, Stuart M. Curbishley, Marco Carbone, Paul Richardson, Sulleman Moreea, C. Anne McCune, Stephen D. Ryder, Roger W. Chapman, Annarosa Floreani, David E. Jones, Cristina de Min, David H. Adams, Pietro Invernizzi – 23 March 2018 – NI‐0801 is a fully human monoclonal antibody against chemokine (C‐X‐C motif) ligand 10 (CXCL10), which is involved in the recruitment of inflammatory T cells into the liver. The safety and efficacy of NI‐0801 was assessed in patients with primary biliary cholangitis.

Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD

Cyrielle Caussy, Cynthia Hsu, Min‐Tzu Lo, Amy Liu, Ricki Bettencourt, Veeral H. Ajmera, Shirin Bassirian, Jonathan Hooker, Ethan Sy, Lisa Richards, Nicholas Schork, Bernd Schnabl, David A. Brenner, Claude B. Sirlin, Chi‐Hua Chen, Rohit Loomba, Genetics of NAFLD in Twins Consortium – 23 March 2018 – Previous studies have shown that gut‐microbiome is associated with nonalcoholic fatty liver disease (NAFLD). We aimed to examine if serum metabolites, especially those derived from the gut‐microbiome, have a shared gene‐effect with hepatic steatosis and fibrosis.

Liver‐enriched transcription factor expression relates to chronic hepatic failure in humans

Jorge Guzman‐Lepe, Eduardo Cervantes‐Alvarez, Alexandra Collin de l'Hortet, Yang Wang, Wendy M. Mars, Yoshinao Oda, Yuki Bekki, Masahiro Shimokawa, Huanlin Wang, Tomoharu Yoshizumi, Yoshihiko Maehara, Aaron Bell, Ira J. Fox, Kazuki Takeishi, Alejandro Soto‐Gutierrez – 23 March 2018 – The mechanisms by which the liver fails in end‐stage liver disease remain elusive. Disruption of the transcription factor network in hepatocytes has been suggested to mediate terminal liver failure in animals. However, this hypothesis remains unexplored in human subjects.

Sphingosine kinase 1 promotes liver fibrosis by preventing miR‐19b‐3p‐mediated inhibition of CCR2

Tian Lan, Changzheng Li, Guizhi Yang, Yue Sun, Lihang Zhuang, Yitao Ou, Hui Li, Genshu Wang, Tatiana Kisseleva, David Brenner, Jiao Guo – 23 March 2018 – Chronic liver disease mediated by activation of hepatic stellate cells (HSCs) and Kupffer cells (KCs) leads to liver fibrosis. Here, we aimed to investigate the molecular mechanism and define the cell type involved in mediating the sphingosine kinase (SphK)1‐dependent effect on liver fibrosis. The levels of expression and activity of SphK1 were significantly increased in fibrotic livers compared with the normal livers in human.

PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1

Zhiqiang Chen, Wen Gao, Liyong Pu, Long Zhang, Guoyong Han, Xueliang Zuo, Yao Zhang, Xiangcheng Li, Hongbing Shen, Jindao Wu, Xuehao Wang – 23 March 2018 – Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. PRDI‐BF1 and RIZ homology domain containing 8 (PRDM8) is a key regulator in neural development and testis steroidogenesis; however, its role in liver carcinogenesis remains to be investigated. In this study, PRDM8 was found to be down‐regulated in HCC, which was linked with shorter recurrence‐free survival.

Anti‐tumoral effects of exercise on hepatocellular carcinoma growth

Uttara Saran, Maria Guarino, Sarai Rodríguez, Cedric Simillion, Matteo Montani, Michelangelo Foti, Bostjan Humar, Marie V. St‐Pierre, Jean‐François Dufour – 22 March 2018 – Regular physical exercise has many beneficial effects, including antitumor properties, and is associated with a reduced risk of developing hepatocellular carcinoma (HCC). Less is known about the impact of exercise on HCC growth and progression.

Subscribe to